Sanofi-Aventis Details Plans for Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
As Big Pharma strives to educate Wall Street on the promise of emerging markets, Sanofi-Aventis has come out swinging: in a statistic-filled July 2 analyst forum, top executives noted they have a bigger market share and more experience than rivals in some of the fastest-growing countries
You may also be interested in...
Chinese Premier Wen Jiabao Allocates Healthcare Investment, But Essential Drug List Delayed Again
SHANGHAI - China's State Council issued additional healthcare reform plans July 8 to detail the goals of the country's ambitious reform plan. However, the release of the long-awaited essential drug list will be delayed to the end of this year, which was expected to be issued by June
South of the Border: Sanofi’s Tailored Approach To Emerging Markets
Sanofi’s recent acquisition of Medley, Brazil’s leading generics manufacturer, reflects its strategy of going local — and generic — in emerging markets.
China Vows To Invest RMB 850 Billion In Healthcare System By 2011
SHANGHAI - China's State Council has approved a three-year plan to implement part of the country's sweeping health system reforms, and plans to invest RMB 850 billion ($124 billion) into the sector by 2011, according to a report published on the Chinese government's official Web site